SHR-1209 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypercholesteremia
Conditions
Hypercholesteremia
Trial Timeline
Aug 30, 2018 → May 28, 2019
NCT ID
NCT03634436About SHR-1209 + Placebo
SHR-1209 + Placebo is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Hypercholesteremia. The current trial status is completed. This product is registered under clinical trial identifier NCT03634436. Target conditions include Hypercholesteremia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03944109 | Phase 1/2 | Completed |
| NCT03634436 | Phase 1 | Completed |
Competing Products
5 competing products in Hypercholesteremia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atorvastatin, Lipitor | Astellas Pharma | Approved | 85 |
| Rosuvastatin + HMG CoA inhibitor | Shionogi | Approved | 85 |
| Rosuvastatin calcium | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin + Atorvastatin | AstraZeneca | Phase 3 | 77 |
| MK-0524A + ER Niacin + Placebo | Merck | Phase 3 | 77 |